Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

NCT06896110 is registered in ClinicalTrials.gov with Andrew P. Groves as lead sponsor.

NCT NCT06896110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06896110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
Lead sponsor
Andrew P. Groves
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
June 5, 2025
Completion date
March 31, 2027
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, idh-mutant, grade 4, diffuse hemispheric glioma, h3 g34-mutant, diffuse midline glioma (dmg), glioblastoma (gbm), gliosarcoma of brain